Hybrid vaccines based on the Li-Key peptide vaccine technology are being developed by NuGenerex Immuno-Oncology (previously Antigen Express and wholly-owned subsidiary of Generex) for the prevention of COVID-2019 infections. The proprietary technology utilises the 4-amino acid Li-Key peptide which is chemically linked to synthetic peptides that mimic as essential epitope of the virus. The Li-Key peptide by interacting with the allosteric site of MHC Class II molecules causes displacement of the existing antigens and anchors the chemically linked viral epitope to the antigen binding domain. This interaction allows the hybrid vaccine to bypass all requirements for antigen processing and results in enhanced activation of CD4+ T cells and improves long-term immunologic memory. The hybrid vaccine is composed of naturally occurring amino acids which helps in prevention of adverse reactions. Early stage development is ongoing in the US.
NuGenerex Immuno-Oncology is seeking partners for the development of hybrid vaccines for prevention of COVID-2019 infections  .
The use of Antigen Express's Li-Key technology in the development of immunotherapeutic vaccines is covered by a granted patent in Japan, international counterparts in the US, Europe, Australia, and China, and a pending application in Canada  .